Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

Conditions:   Hematopoietic and Lymphoid Cell Neoplasm;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Histiocytic and Dendritic Cell Neoplasm;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Lymphoma;   Recurrent Malignant Germ Cel l Tumor;   Recurrent Malignant Glioma;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Recurrent WHO Grade II Glioma;   Refractory Ependymoma;   Refractory Ewing Sarcoma;   Refractory Hepatoblastoma;   Refractory Histiocytic and Dendritic Cell Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Lymphoma;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Pr imitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Refractory WHO Grade II Glioma;   Wilms Tumor Intervention:   Drug: Selpercatinib Sponsor:   National Cancer Institute (NCI) Not yet recru...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials